Log in
Enquire now

List of OliX Pharmaceuticals patents

List of OliX Pharmaceuticals patents
List of I-Shou University patents
List of Arc Bio patents
List of Southern Illinois University Carbondale patents
List of companies in MindWorks Ventures's investment portfolio
List of funding rounds for EpiVax (company)
Patents where
Current Assignee
Name
is
OliX PharmaceuticalsOliX Pharmaceuticals
Name
Description
Patent Applicant
Current Assignee
Inventor
Patent Jurisdiction
Patent Number
Date of Patent
‌
US Patent 10125362 RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor

Patent 10125362 was granted and assigned to OliX Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10125362
November 13, 2018
‌
US Patent 11591600 Long double-stranded RNA for RNA interference

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11591600
February 28, 2023
‌
US Patent 10064801 RNA complexes that inhibit melanin production

Patent 10064801 was granted and assigned to OliX Pharmaceuticals on September, 2018 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10064801
September 4, 2018
‌
US Patent 10947541 Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

Patent 10947541 was granted and assigned to OliX Pharmaceuticals on March, 2021 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10947541
March 16, 2021
‌
US Patent 10358648 Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1

Patent 10358648 was granted and assigned to OliX Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10358648
July 23, 2019
‌
US Patent 10829760 Nucleic acid molecules inducing RNA interference, and uses thereof

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10829760
November 10, 2020
‌
US Patent 10059949 Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3

Patent 10059949 was granted and assigned to OliX Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10059949
August 28, 2018
‌
US Patent 11040057 Pharmaceutical compositions and methods for potentiating gene silencing

Patent 11040057 was granted and assigned to OliX Pharmaceuticals on June, 2021 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11040057
June 22, 2021
‌
US Patent 10829761 Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10829761
November 10, 2020
‌
US Patent 10883105 RNA-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor

Patent 10883105 was granted and assigned to OliX Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10883105
January 5, 2021
‌
US Patent 10590423 Treatment of age-related macular degeneration using RNA complexes that target MyD88 or TLR3

Patent 10590423 was granted and assigned to OliX Pharmaceuticals on March, 2020 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10590423
March 17, 2020
‌
US Patent 10519449 Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB

Patent 10519449 was granted and assigned to OliX Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10519449
December 31, 2019
‌
US Patent 10512600 RNA complexes that inhibit melanin production

Patent 10512600 was granted and assigned to OliX Pharmaceuticals on December, 2019 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10512600
December 24, 2019
‌
US Patent 10301628 Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor

Patent 10301628 was granted and assigned to OliX Pharmaceuticals on May, 2019 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
10301628
May 28, 2019
‌
US Patent 11118184 Asymmetric siRNA for inhibiting expression of male pattern hair loss target gene

Patent 11118184 was granted and assigned to OliX Pharmaceuticals on September, 2021 by the United States Patent and Trademark Office.

OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
OliX Pharmaceuticals
United States Patent and Trademark Office
United States Patent and Trademark Office
11118184
September 14, 2021
15 results
0 selected
15 results
0 selected
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us